HealthStat International has launched a portable home device A-Pulse CASPal to measure blood pressure from a person’s aorta. This reading is a better indicator of the risk of heart attacks and strokes than one taken the conventional way from the arm. The device offers a non-invasive way of getting a reading of the blood pressure from the aorta, the main vessel which carries oxygenated blood out of the heart to the rest of the body.

Integrated Medical Systems Inc has received CE Mark certification for its MedEx 1000(TM) “suitcase” intensive care unit (ICU). The MedEx 1000 is a portable unit intended to supply ICU functionality, such as physiological monitoring, electrocardiogram, invasive pressure monitoring, non-invasive blood pressure monitoring, temperature, blood oxygen saturation and heart rate, low and high rate infusion pumps, a fluid warmer and a ventilator with carbon dioxide monitoring capabilities, for adult and pediatric patients.  This certification permits the marketing, sale and use of the MedEx 1000 in Europe.

European regulators have approved Boston Scientific Corp’s plans to market a system that remotely monitors patients that have been implanted with cardiac defibrillators. Boston Scientific’s patient management system, dubbed Latitude, incorporates a blood pressure monitor and collects data on the performance of person’s heart and that of the defibrillator itself. Latitude reports information it collects back to doctors.

Opto Circuits India Ltd.’s subsidiary, Mediaid Inc., received Food and Drug Administration approval for its key vital signs monitoring products. The approval for marketing for model 900 and model 960 opens up the U.S. hospital market for Mediaid products. The model 900 and 960 devices monitor blood oxygen, blood pressure and temperature for a complete and quick assessment of vital signs.

Pharmacopeia announced that the results from its s Phase 2a clinical trial evaluating PS433540, its first-in-class Dual Acting Receptor Antagonist (DARA), will be presented as a late-breaking clinical trial at the 23rd Annual Scientific Meeting and Exposition of the American Society of Hypertension (ASH) in New Orleans. PS433540 is being developed as a potential treatment for both hypertension and diabetic nephropathy, and is the first and only blood pressure product candidate in development that possesses two validated mechanisms of action in a single compound.